NLRP3 and glycogen storage disease VI: In an endeavour to identify potential therapies for the treatment of inflammasome‐mediated diseases, we screened an in‐house bioactive compound library against immortalised mouse bone marrow‐derived macrophages (iBMDMs) pre‐treated with LPS and challenged with prototypic NLRP3 agonists nigericin and silica.30, 31